Revuforj: New Hope For Patients With Acute Leukaemia

On 15 November 2024, the US Food and Drug Administration (FDA) approved a new drug called Revuforj (revumenib) for the treatment of adult and paediatric patients aged 1 year and older with relapsed or refractory…



